Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024New CM24 biomarkers data presented during the third quarter of ...

Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identif ...

IPI, ipilimumab; NIVO, nivolumab. Median follow-up for OS was 43. ... product information currently provided by the manufacturer of each drug to be administered to verify approved uses, the dosage, ...

On August 22, 2024, the U.S. Food and Drug Administration (“FDA”) approved the companies’ KP ... 1305 alone and in combination with BNT327/PM8002 in various solid tumor indications. Additional trials ...

For the most current information about the device indications for the therapeutic products in this group, go to: ...

Q3 2024 Earnings Call Transcript October 31, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

The FDA will determine whether nivolumab should be added as standard treatment for stage 3 or 4 Hodgkin lymphoma. However, because nivolumab is already approved for other indications, Friedberg ...

Once approved, this would represent our 9th approved product with ENHANZE. Nivolumab subcutaneous ... the additional Roche and Chugai drug, just whether target indication is like after a Phase ...

The FDA will determine whether nivolumab should become standard treatment for stage 3 or 4 Hodgkin lymphoma. Because nivolumab is already approved for other indications and is less expensive than some ...

We continue to see considerable unmet need across indications ... subcutaneous formulation of nivolumab which, as Chris mentioned, is expected to receive FDA approval by year-end.

Overall, the results with Keytruda are very similar to that seen with BMS’ PD-1 inhibitor Opdivo (nivolumab), which was approved by the FDA for the same HCC indication in September 2017.